Airgain Signs Strategic Memorandum of Understanding With COMPAL, a Global Fortune 500 Leader, on Airgain’s 5G Smart FWA Technology
30.5.2024 15:55:00 EEST | Business Wire | Press release
Airgain, Inc. (NASDAQ: AIRG), a leading provider of wireless connectivity solutions, has signed a strategic Memorandum of Understanding (MOU) with Compal Electronics, Inc. (TAIEX: 2324), a global fortune 500 leader in smart device manufacturing, on a comprehensive plan for commercialization of a 5G Smart Fixed Wireless Access (FWA) technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530558164/en/
Yiyun Chang, Vice President at Compal Electronics, Inc. (left), shaking hands with Dr. Ali Sadri, CTO of Airgain, Inc., after signing a strategic MOU. (Photo: Business Wire)
The agreement signals a major step towards enabling mass production of this transformative technology which has the potential to substantially enhance 5G customer experience and mobile network operator (MNO) capabilities.
Airgain Smart LanternTM uses patent-pending smart beamforming technology to simplify end-user FWA deployment as well as reducing truck roll and professional installation, by automatically determining the direction of the best received and transmitted signal from the 5G cellular base station (gNb).
Preliminary testing results indicate a performance enhancement exceeding 25% in both throughput and range when compared to conventional indoor and outdoor omnidirectional Fixed Wireless Access (FWA) Customer Premises Equipment (CPE).
The MOU commits the two companies to a collaboration which will see them evaluate the technology’s 5G KPI enhancements and assess the feasibility, effectiveness, and opportunities for original equipment manufacturer (OEM) and original device manufacturer (ODM) for FWA device development.
At the heart of the innovation is Airgain’s first-of-its-kind smart antenna technology for 5G mid-band and C-band frequencies, and novel beamforming algorithms. When combined with COMPAL’s expertise in developing FWA modules leveraging leading 5G chipset providers, this will deliver a powerful value proposition to their customers.
According to the forecast presented in the Ericsson Mobility Report, the Fixed Wireless Access (FWA) market is projected to reach a valuation of $67 billion by the year 2028, which equates to a Compound Annual Growth Rate (CAGR) of 16% year-over-year. Smart Lantern's FWA technology holds the potential to significantly drive the adoption of FWA technology among Mobile Network Operators (MNOs).
Dr. Ali Sadri, CTO of Airgain, Inc., heralded the MOU as a significant moment in bringing Smart LanternTM to market, adding:
“As we embark on this ground-breaking journey towards enabling commercialization, the signing of this MOU with COMPAL signifies a strategic leap forward in realizing the full potential of our innovative product, Smart LanternTM.
“Having demonstrated its feasibility and generated tremendous excitement at Mobile World Congress, this MOU underscores our commitment to translating that enthusiasm into tangible market success. This momentous partnership solidifies Airgain's position as a trailblazer in delivering cutting-edge solutions that shape the future landscape of wireless communication.”
Yiyun Chang, Vice President at Compal Electronics, Inc., said:
“COMPAL’s mission is to foster collaborative innovation and make ideas happen. Our collaboration with Airgain is built on shared dedication to pushing the boundaries of what's possible in the telecommunications industry. We are confident that this partnership will not only meet but exceed the expectations of telecom equipment manufacturers (TEMs), MNOs, and system integrators (SI).
“Together, we are poised to redefine the standards and capabilities of wireless communication, reinforcing COMPAL’s commitment to delivering state-of-the-art solutions that shape the future of connectivity.”
For more information about Smart LanternTM visit airgain.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530558164/en/
Contact information
Airgain Media Contact
Martyn Gettings +44 7831 158416
pr@airgain.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom